|
?:abstract
|
-
Corona virus disease 2019 (COVID-19) is a viral pneumonia disease with a severe outbreak in Wuhan, China, in December 2019, which is caused by coronavirus-2 (SARSCoV-2) with severe acute respiratory syndrome There have been tremendous advances in in-vitro diagnostic (IVD) assays for corona virus disease 2019 (COVID-19) The initial diagnostic of COVID-19 is based on the test of Sputum, Blood and SWAB of throat and nose The main IVD assays used for COVID-19 based on real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours but shortened to minimum of 45 hr Another method of interest is the point-of-care (POC) molecular assay that decreased the assay duration to just 5 min and has been approved by the United States Food and Drug Administration (USFDA) under emergency use authorization (EUA) A range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19 The most prominent IAs are automated chemiluminescent IA (CLIA), ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin produced in persons in response to SARS-CoV-2 infection i e, immunoglobulin (IgM) and immunoglobulin (IgG) In this review, we provide a brief introduction of the general features of SARS-CoV-2 and discuss various diagnostic method of COVID-19, which may be helpful in offering novel insights and potential therapeutic targets for eradiating the SARS-CoV-2 infection
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}